{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:06:01Z","timestamp":1771459561521,"version":"3.50.1"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Thrombophilia testing is frequently performed in both seemingly provoked and unprovoked portal vein thrombosis (PVT), yet the clinical implications of these expensive laboratory tests are unknown. We investigated the frequency of clinical management changes in patients with newly diagnosed PVT. This is a retrospective analysis of adult patients with a newly diagnosed PVT at a single institution. The primary outcome is change in clinical management, defined as documented change in choice, dose, or duration of anticoagulation, future thromboprophylaxis, or counseling of asymptomatic family members. Five-hundred and forty-four patients with PVT were identified, 438 (80.5%) of whom had an identifiable pretesting provoking factor, most commonly cirrhosis (39.2%). Two-hundred ninety-one patients (53.5%) had at least one hypercoagulable laboratory test performed. The most frequently positive test was\n                      <jats:italic toggle=\"yes\">PAI-1<\/jats:italic>\n                      polymorphism, followed by elevated homocysteine and\n                      <jats:italic toggle=\"yes\">MTHFR<\/jats:italic>\n                      mutational analysis. However, the only test that was frequently positive and consistently altered management was\n                      <jats:italic toggle=\"yes\">JAK2<\/jats:italic>\n                      mutational analysis (15.3%). Factor V Leiden was commonly positive but rarely changed clinical decision-making (1.5%), as was flow cytometric testing for paroxysmal nocturnal hemoglobinuria (0.8%), and antiphospholipid antibodies (0.7%). Patients with cirrhosis rarely had thrombophilia testing results that were clinically significant. A rough cost estimate was dramatically reduced from $231\u200a000 to $76\u200a000 if only clinically meaningful tests were employed in the hypercoagulable work-up. These results highlight the need for focused thrombophilia testing in patients with PVT.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mbc.0000000000000901","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T17:23:39Z","timestamp":1582737819000},"page":"213-218","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["The utility of thrombophilia testing in patients with newly diagnosed portal vein thrombosis"],"prefix":"10.1097","volume":"31","author":[{"given":"Douglas","family":"Tremblay","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Naymagon","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Troy","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Cromwell","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen","family":"Edwards","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Schiano","sequence":"additional","affiliation":[{"name":"Division of Liver Diseases, Recanati\/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Mascarenhas","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tisch Cancer Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20251202","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3748\/wjg.v12.i13.2115","article-title":"Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies","volume":"12","author":"Ogren","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R2-20251202","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/hep.20591","article-title":"Risk factors for thrombophilia in extrahepatic portal vein obstruction","volume":"41","author":"Primignani","year":"2005","journal-title":"Hepatology"},{"key":"R3-20251202","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1160\/TH07-08-0526","article-title":"Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis","volume":"99","author":"Dentali","year":"2008","journal-title":"Thromb Haemost"},{"key":"R4-20251202","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bpg.2016.11.002","article-title":"Testing for thrombophilia in mesenteric venous thrombosis \u2013 retrospective original study and systematic review","volume":"31","author":"Zarrouk","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R5-20251202","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1111\/j.1538-7836.2008.03055.x","article-title":"Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis","volume":"6","author":"Coppens","year":"2008","journal-title":"J Thromb Haemost"},{"key":"R6-20251202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2141.2008.07339.x","article-title":"Does thrombophilia testing help in the clinical management of patients?","volume":"143","author":"Middeldorp","year":"2008","journal-title":"Br J Haematol"},{"key":"R7-20251202","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11239-019-01930-w","article-title":"Appropriateness of thrombophilia testing in patients in the acute care setting and an evaluation of the associated costs","volume":"49","author":"Virparia","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"R8-20251202","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1161\/STROKEAHA.110.595199","article-title":"Testing for inherited thrombophilias in arterial stroke: can it cause more harm than good?","volume":"41","author":"Morris","year":"2010","journal-title":"Stroke"},{"key":"R9-20251202","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/bloodadvances.2017009514","article-title":"A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: impact on management","volume":"1","author":"Gavva","year":"2017","journal-title":"Blood Adv"},{"key":"R10-20251202","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3945\/ajcn.112.044545","article-title":"Common genetic loci influencing plasma homocysteine concentrations and their effect on risk of coronary artery disease","volume":"98","author":"van Meurs","year":"2013","journal-title":"Am J Clin Nutr"},{"key":"R11-20251202","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1001\/archinte.167.5.497","article-title":"No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study","volume":"167","author":"Bezemer","year":"2007","journal-title":"Arch Intern Med"},{"key":"R12-20251202","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10654-013-9825-8","article-title":"Risk of venous thromboembolism associated with single and combined effects of Factor V Leiden, prothrombin 20210A and methylenetethraydrofolate reductase C677T: a meta-analysis involving over 11,000 cases and 21,000 controls","volume":"28","author":"Simone","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"R13-20251202","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMra1700365","article-title":"Thrombophilia testing and venous thrombosis","volume":"377","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"key":"R14-20251202","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/hep.22772","article-title":"American association for the study liver D. Vascular disorders of the liver","volume":"49","author":"DeLeve","year":"2009","journal-title":"Hepatology"},{"key":"R15-20251202","doi-asserted-by":"crossref","first-page":"322","DOI":"10.7326\/0003-4819-135-5-200109040-00008","article-title":"A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism","volume":"135","author":"Middeldorp","year":"2001","journal-title":"Ann Intern Med"},{"key":"R16-20251202","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00001721-200309000-00002","article-title":"Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?","volume":"14","author":"Procare","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"key":"R17-20251202","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejim.2016.02.023","article-title":"Do incident and recurrent venous thromboembolism risks truly differ between heterozygous and homozygous Factor V Leiden carriers? A retrospective cohort study","volume":"30","author":"Perez Botero","year":"2016","journal-title":"Eur J Intern Med"},{"key":"R18-20251202","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1038\/bcj.2016.103","article-title":"Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients","volume":"6","author":"De Stefano","year":"2016","journal-title":"Blood Cancer J"},{"key":"R19-20251202","doi-asserted-by":"crossref","first-page":"E61","DOI":"10.1002\/ajh.24993","article-title":"Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: the Mayo clinic experience with 84 consecutive cases","volume":"93","author":"Lavu","year":"2018","journal-title":"Am J Hematol"},{"key":"R20-20251202","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.13335","article-title":"Outcomes of splanchnic vein thrombosis in patients with myeloproliferative neoplasms in a single center experience","volume":"104","author":"Tremblay","year":"2020","journal-title":"Eur J Haematol"},{"key":"R21-20251202","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jhep.2017.04.021","article-title":"Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: a prospective cohort study","volume":"67","author":"Poisson","year":"2017","journal-title":"J Hepatol"},{"key":"R22-20251202","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2009.08022.x","article-title":"Clinical guidelines for testing for heritable thrombophilia","volume":"149","author":"Baglin","year":"2010","journal-title":"Br J Haematol"},{"key":"R23-20251202","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1182\/blood-2013-07-518423","article-title":"The ASH Choosing Wisely(R) campaign: five hematologic tests and treatments to question","volume":"122","author":"Hicks","year":"2013","journal-title":"Blood"},{"key":"R24-20251202","doi-asserted-by":"crossref","first-page":"457","DOI":"10.4065\/83.4.457","article-title":"JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients","volume":"83","author":"Pardanani","year":"2008","journal-title":"Mayo Clin Proc"}],"container-title":["Blood Coagulation &amp; Fibrinolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T10:00:14Z","timestamp":1764669614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MBC.0000000000000901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mbc.0000000000000901","relation":{},"ISSN":["0957-5235","1473-5733"],"issn-type":[{"value":"0957-5235","type":"print"},{"value":"1473-5733","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]}}}